Shenzhen New Industries Biomedical (300832) — Cash Flow Quality Index

Latest as of September 2025: 1.40x

Shenzhen New Industries Biomedical (300832) has a Cash Flow Quality Index of 1.40x as of September 2025. Operating cash flow of CN¥606.21 Million exceeds net income of CN¥433.73 Million, indicating high earnings quality where cash backs reported profits. Explore Shenzhen New Industries Biomedical cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.

Cash Flow Quality Index

1.40x
Operating CF / Net Income

Operating Cash Flow

CN¥606.21 Million
CNY

Net Income

CN¥433.73 Million
CNY

Data as of

Sep 2025
Most recent filing

Shenzhen New Industries Biomedical Cash Flow Quality Index (2012–2024)

Historical Cash Flow Quality Index for Shenzhen New Industries Biomedical across 13 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see cash efficiency ratio of Shenzhen New Industries Biomedical.

Annual Cash Flow Quality Index for Shenzhen New Industries Biomedical (2012–2024)

Year-by-year earnings quality comparison for Shenzhen New Industries Biomedical.

Year Quality Index Operating CF (CNY) Net Income YoY Change
2024 0.74x CN¥1.36 Billion CN¥1.83 Billion ▼ -13.5%
2023 0.86x CN¥1.42 Billion CN¥1.65 Billion ▲ +18.3%
2022 0.72x CN¥962.39 Million CN¥1.33 Billion ▼ -8.7%
2021 0.79x CN¥773.22 Million CN¥973.70 Million ▼ -23.6%
2020 1.04x CN¥976.65 Million CN¥939.15 Million ▼ -3.4%
2019 1.08x CN¥831.73 Million CN¥772.61 Million ▲ +6.4%
2018 1.01x CN¥701.97 Million CN¥694.00 Million ▲ +3.7%
2017 0.97x CN¥524.73 Million CN¥538.21 Million ▼ -9.5%
2016 1.08x CN¥486.81 Million CN¥451.69 Million ▼ -12.2%
2015 1.23x CN¥305.93 Million CN¥249.12 Million ▲ +22.5%
2014 1.00x CN¥253.47 Million CN¥252.87 Million ▲ +2.4%
2013 0.98x CN¥138.33 Million CN¥141.27 Million ▲ +31.8%
2012 0.74x CN¥55.80 Million CN¥75.12 Million
Cash Flow Quality Index = Operating Cash Flow / Net Income. Ratios above 1.0x indicate cash-backed earnings.